1,374 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
The 5 Best Dividend Stocks in Cholesterol Drugs https://www.fool.com/investing/2017/05/30/the-5-best-dividend-stocks-in-cholesterol-drugs.aspx?source=iedfolrf0000001 May 30, 2017 - Looking for great dividend stocks of companies that make cholesterol drugs? Check out Amgen, AstraZeneca, Novartis, Pfizer, and Sanofi.
Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada http://www.zacks.com/stock/news/262195/intercepts-icpt-liver-drug-ocaliva-approved-in-canada?cid=CS-ZC-FT-262195 May 29, 2017 - Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.
Kite Pharma Cancer Drug BLA Gets Priority Review Status http://www.zacks.com/stock/news/262178/kite-pharma-cancer-drug-bla-gets-priority-review-status?cid=CS-ZC-FT-262178 May 29, 2017 - Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.
3 Top Dividend Stocks in Generic Drugs https://www.fool.com/investing/2017/05/26/3-top-dividend-stocks-in-generic-drugs.aspx?source=iedfolrf0000001 May 26, 2017 - Why Pfizer, Novartis, and Sanofi rank at the top of all dividend stocks in the generic-drug industry.
GlaxoSmithKline's New CEO Is Off to a Good Start https://www.fool.com/investing/2017/05/26/glaxosmithklines-new-ceo-is-off-to-a-good-start.aspx?source=iedfolrf0000001 May 26, 2017 - The latest quarter gave investors in this dividend stock an encouraging glimpse into the future.
I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug https://www.fool.com/investing/2017/05/25/i-still-cant-believe-juno-therapeutics-spent-464-m.aspx?source=iedfolrf0000001 May 25, 2017 - A costly learning exercise.
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline http://www.zacks.com/stock/news/261816/alnylam-pharmaceuticals-alny-progressing-well-on-pipeline?cid=CS-ZC-FT-261816 May 25, 2017 - We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler http://www.zacks.com/stock/news/261810/novartis-nvs-reports-positive-data-on-ultibro-breezhaler?cid=CS-ZC-FT-261810 May 25, 2017 - Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.
United States Steel & Carnegie Pension Fund Buys United States Steel Corp, Unilever NV, ... http://www.gurufocus.com/news/524780/united-states-steel--carnegie-pension-fund-buys-united-states-steel-corp-unilever-nv-enbridge-inc-sells-spdr-sp-500-international-paper-co-unilever-plc May 24, 2017 - United States Steel & Carnegie Pension Fund Buys United States Steel Corp, Unilever NV, Enbridge Inc, Sells SPDR S&P 500, International Paper Co, Unilever PLC, Stocks: ENB,FBHS,X,UN,SPY,UL,COST,IP,SE,CHKP,DIS,, release date:May 24, 2017
ASM International NV (ASMIY) Investor Presentation - Slideshow https://seekingalpha.com/article/4075890-asm-international-nv-asmiy-investor-presentation-slideshow?source=feed_all_articles May 23, 2017 - The following slide deck was published by ASM International N.V. in conjunction with this event.
<<<Page 118>